☆ 4.6 Letter

Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sezary syndrome

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients

Adele de Masson et al.

Summary: Mogamulizumab treatment in CTCL patients resulted in skin rashes in 32% of patients. These rashes were characterized by CD163(+) granulomatous and/or CD8(+) lichenoid skin infiltrate. Two macrophage-derived chemokines, CXCL9 and CXCL11, were overexpressed in these rashes. Patients with rash had a higher frequency of TIGIT(+) and PD1(+) reactive blood T cells at baseline, which decreased with mogamulizumab treatment.

BLOOD (2022)

Add to Collection

Article Dermatology

Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome

Kelsey E. Hirotsu et al.

Summary: The study highlights the heterogeneous clinical presentation of mogamulizumab-associated rash in patients with MF or SS, making it challenging to clinically distinguish from disease relapse or progression. Recognition of common clinical presentations can help prevent unnecessary discontinuation of treatment with mogamulizumab.

JAMA DERMATOLOGY (2021)

Add to Collection

Article Hematology